Gefitinib enhances cisplatin-induced death and lowers invasive capacity in putative cancer stem cells.

<p>(A) MTS assay comparing the survival curves of control JLO-1 to 2 µM gefitinib-treated JLO-1 when subjected to increasing doses of cisplatin. Gefitinib-treated JLO-1 lost their viability at noticeably lower doses in comparison to control cells. (B) Matrigel invasion assay comparing relative number of cells invaded between control, EGF-treated, and Gefitinib-treated JLO-1. (C) Representative photographs of the bottom surfaces of the invasion chambers, showing clear differences in the number of invaded cells between the three samples.